Printer Friendly
The Free Library
14,599,653 articles and books
Member login
User name  
Password 
 
Join us Forgot password?

Biovail to Present at the UBS 2005 Global Pharmaceuticals Conference.


TORONTO -- Biovail Corporation (NYSE NYSE

See: New York Stock Exchange
:BVF BVF Biovail Corporation (stock symbol)
BVF Berufsverband der Frauenärzte eV (Muenchen, Germany)
BVF Bearing Versus Frequency
)(TSX TSX Toronto Stock Exchange (TSE before April, 2002)
TSX Transfer from Stack Pointer to Index
TSX True Space Extension
:BVF) today announced that the Company will present at the UBS UBS Union Bank of Switzerland
UBS United Bible Societies
UBS United Blood Services
UBS United Buying Service
UBS Used Bookstore
UBS University Business Services
UBS Universal Building Society (UK)
UBS Ulaanbaatar Broadcasting System
 2005 Global Pharmaceuticals Conference at the Grand Hyatt New York hotel in New York City New York City: see New York, city.
New York City

City (pop., 2000: 8,008,278), southeastern New York, at the mouth of the Hudson River. The largest city in the U.S.
.

Biovail's presentation is scheduled for Tuesday, May 24, 2005, at 1:30 pm EDT. A live and archived Web cast, in addition to presentation slides, will be available on the Investor Relations page of Biovail's Web site, www.biovail.com.

About Biovail Corporation

Biovail Corporation is a specialty pharmaceutical company, engaged in the formulation, clinical testing, registration, manufacture and commercialization of pharmaceutical products utilizing advanced drug-delivery technologies. For more information about Biovail, visit the company's Web site at www.biovail.com.

For further information, please contact Ken Howling at 905-286-3000 or send inquiries to ir@biovail.com.

"Safe Harbor" Statement Under the Private Securities Litigation Reform Act The Private Securities Litigation Reform Act of 1995 (PSLRA) implemented several significant substantive changes affecting certain cases brought under the federal securities laws, including changes related to pleading, discovery, liability, class representation and awards fees and  of 1995

To the extent any statements made in this release contain information that is not historical, these statements are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. We have based these forward-looking statements on our current expectations and projections about future events. Our actual results could differ materially from those discussed in, or implied by, these forward-looking statements. Forward-looking statements are identified by words such as "believe," "anticipate," "expect," "intend," "plan," "will," "may" and other similar expressions. In addition, any statements that refer to expectations, projections or other characterizations of future events or circumstances are forward-looking statements. Forward-looking statements include, but are not necessarily limited to, risks and uncertainties, including the difficulty of predicting U.S. Food and Drug Administration and Canadian Therapeutic Products Directorate Therapeutic Products Directorate (TPD) is a Canadian federal authority that regulates pharmaceutical drugs and medical devices for human use, a role performed by the Food and Drug Administration in the United States.  approvals, acceptance and demand for new pharmaceutical products, the impact of competitive products and pricing, new product development and launch, reliance on key strategic alliances, availability of raw materials and finished products, the regulatory environment, tax rate assumptions, the outcome of legal proceedings, fluctuations in operating results and other risks detailed from time to time in the Company's filings with the Securities and Exchange Commission and the Ontario Securities Commission The Ontario Securities Commission (OSC) is a regulatory agency which administers and enforces securities legislation in the Canadian province of Ontario. The OSC is an Ontario Crown corporation which reports to the Ontario legislature through the Minister of Finance. . Biovail undertakes no obligation to update or revise any forward-looking statement.
COPYRIGHT 2005 Business Wire
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2005, Gale Group. All rights reserved. Gale Group is a Thomson Corporation Company.

 Reader Opinion

Title:

Comment:



 

Article Details
Printer friendly Cite/link Email Feedback
Publication:Business Wire
Geographic Code:1CANA
Date:May 20, 2005
Words:366
Previous Article:AT&T to Hold 2005 Annual Meeting in Denver.
Next Article:Fitch Rates Florida BOE PECO $365.44MM 1996 Series A & 1999 Series C Ref Bonds 'AAA'.
Topics:



Related Articles
Biovail Corporation to Present at UBS Warburg Global Specialty Pharmaceutical Conference.
Biovail to Present at the Morgan Stanley Third Annual Global Healthcare Unplugged Conference.
Biovail to Present at the UBS Leveraged Finance Conference.
Biovail to Present at the Bear Stearns 14th Annual Global Credit Conference.
Biovail to Present at the Goldman Sachs Twenty-Sixth Annual Global Healthcare Conference.
Biovail to Present at the UBS 2005 Global Life Sciences Conference.
Biovail to Present at the UBS Global Specialty Pharmaceuticals Conference.
Biovail to Present at the UBS 2006 Global Life Sciences Conference.
UBS Global Life Sciences Conference Opens in New York.
Biovail to Present at the Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference.

Terms of use | Copyright © 2009 Farlex, Inc. | Feedback | For webmasters | Submit articles